Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Top Cited Papers
- 31 March 2006
- journal article
- case report
- Published by Elsevier BV in Ophthalmology
- Vol. 113 (3), 363-372.e5
- https://doi.org/10.1016/j.ophtha.2005.11.019
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- ENHANCED EFFICACY ASSOCIATED WITH EARLY TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PEGAPTANIB SODIUMRetina, 2005
- Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Week Results of an Uncontrolled Open-Label Clinical StudyOphthalmology, 2005
- Maximum Tolerated Dose of a Humanized Anti–Vascular Endothelial Growth Factor Antibody Fragment for Treating Neovascular Age-Related Macular DegenerationOphthalmology, 2005
- Bevacizumab suppresses choroidal neovascularisation caused by pathological myopiaBritish Journal of Ophthalmology, 2005
- Inhibitors of Ocular NeovascularizationJAMA, 2005
- Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal AdministrationInvestigative Ophthalmology & Visual Science, 2005
- Pathogenesis of lesions in late age-related macular diseaseAmerican Journal of Ophthalmology, 2004
- Safe and effectiveOphthalmology, 2003
- Comparisons of the Intraocular Tissue Distribution, Pharmacokinetics, and Safety of 125I-Labeled Full-Length and Fab Antibodies in Rhesus Monkeys Following Intravitreal AdministrationToxicologic Pathology, 1999
- REMOVAL OF SUBRETINAL HEMORRHAGE FACILITATED BY PREOPERATIVE INTRAVITREAL TISSUE PLASMINOGEN ACTIVATORRetina, 1994